Roberta Sanfilippo, MD

MD
Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Poster(s):

• (P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS

• (P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION

• (P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY

• (P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER

• (P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS

• (P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA

• (P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.

• (P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES